Plain-English translation of NCT06574360 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating schizophrenia that hasn't responded well to standard antipsychotic medications. Researchers are comparing two treatment combinations: an S1R agonist paired with an NMDA enhancer, versus an S1R agonist paired with a placebo (inactive pill). Both groups will continue taking their regular antipsychotic medications while participating.
Current schizophrenia treatments don't work well enough for everyone, especially people whose symptoms don't improve even after trying multiple medications. This study is exploring whether combining two different types of medication might help people whose illness has been harder to treat.
You likely qualify if…
You likely don't qualify if…
You will continue taking your regular antipsychotic medication while adding either the new medication combination or a placebo to your treatment. Over 8 weeks, you'll visit the clinic at weeks 0, 2, 4, 6, and 8 to have your symptoms checked and report any side effects. At the beginning and end of the study, you'll also complete some cognitive (thinking and memory) tests to see how the treatment affects your brain function.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Taiwan